INTRODUCING
Pelican Ultra-Rapid Platform
A saliva test for COVID-19, the Pelican
COVID-19 Ultra-Rapid Mobile Test is an accurate, non-invasive test with a less-than-30-second time to result.
Introducing Pelican
Sentinel species like the canary are used to detect risks to humans by providing advance warning of a danger
New Home Design bg 1
Early diagnosis is the single most important factor when determining cancer outcomes. Two thirds of cancer can be cured if diagnosed early.
Canary uses proven biomarkers and proprietary nanosensors to map and uncover hidden data in your breath, so cancers and other diseases can be detected early and treated more successfully.
Combined With Ai Powered Intelligence, Canary’s Nanosensor Technology Is Capable Of Predicting The Risk Of Developing Cancers, Identifying Presence Of Diseases, And Predicting And Monitoring Responses To Therapy.
The easy to use and accurate screening test for lung cancer has been used in pilot human field trials with high sensitivity & specificity by analyzing Volatile Organic Compound (VOC) patterns. The 3-minute digital breath test uses raw exhaled breath obtained at normal room temperature with no pre-processing or shipping of samples required & with results available within minutes. The mobile platform is aimed to be used in primary healthcare settings with minimal infrastructure and training required.
Introducing ASU DETECT
INTRODUCING
ASU DETECT®
an ultra-rapid, non-invasive, breath-based real-time detection method for COVID-19
ASU DETECT CV-19
screens for biomarkers and patterns in the breath unique to the SARS-CoV-2 virus. Powered by artificial intelligence, proprietary pattern recognition software, and new sensor technology, the ground-breaking patent-pending platform has the potential to deliver accurate an accurate result
within 1 minute from the start of the test.
Canary grid
DIAGNOSTICS/
DETECTION
Canary’s platforms will be part of a point of care breath-based precision medicine drive to help doctors and clinicians track and evaluate the performance of therapy to optimize treatment applications. Real-time knowledge of how treatment is performing will improve health outcomes and reduce costs.
POINT
OF CARE
Canary Health Techology’s nanoparticle biosensors are mobile point-of-care devices the size of a smart phone. This portability enables a far greater range of access and mobility than other comparable diagnostic products.
PRECISION MEDICINE
Canary’s platforms will be part of a point of care breath-based precision medicine drive to help doctors and clinicians track and evaluate the performance of therapy to optimize treatment applications. Real-time knowledge of how treatment is performing will improve health outcomes and reduce costs.
REAL TIME RESULTS
No pre or post processing or transportation times are required - our sensors send test results to a secure environment where our processing engine analyzes results against existing VOC libraries, delivering results back to patients and practitioners in real-time.
MEDICATION ADHERENCE
The G2 Track platform helps to accurately measure medication adherence by remotely verifying patients have ingested their medication and remain compliant with their treatment. This supports better treatment programs, more timely interventions and urgent patient care, and more improved patient outcomes
BREATH-BASED
TESTING
Our sensors map the volatile organic compounds (VOCs) in a persons breath to a specific disease. In a completely non-invasive way, patients breathe normally into the handheld devices and the breath biomarkers are captured and analyzed and results given in minutes.
From weeks to minutes.
Accurate screening tests can inform you and your doctor or primary care provider within a few minutes.
Canary Unlocks Critical Real-Time Disease, Adherence, Wellness, And Behavioral Data
This will enable effective diagnostic, risk monitoring and management systems, and drive earlier interventions and improved patient health and outcomes. Disease outbreaks surveillance can be done in real-time, enabling immediate response.
